Kovack Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$214K Hold
921
– – 0.01% 950
2026
Q2
$220K Sell
921
-183
-17% -$40.1K 0.01% 959
2026
Q1
$208K Sell
1,104
-52,381
-98% -$9.15M 0.01% 915
2025
Q4
$9.09M Sell
53,485
-748
-1% -$115K 0.42% 44
2025
Q3
$7.15M Sell
54,233
-2,252
-4% -$270K 0.67% 32
2025
Q2
$5.99M Buy
56,485
+2,068
+4% +$225K 0.59% 35
2025
Q1
$6.76M Sell
54,417
-449
-0.8% -$58.6K 0.72% 26
2024
Q4
$6.76M Sell
54,866
-2,806
-5% -$331K 0.66% 30
2024
Q3
$6.43M Buy
57,672
+9,783
+20% +$1.07M 0.68% 28
2024
Q2
$5.11M Sell
47,889
-8,710
-15% -$958K 0.56% 32
2024
Q1
$6.82M Buy
56,599
+26,628
+89% +$3.26M 0.83% 16
2023
Q4
$3.69M Buy
29,971
+23,267
+347% +$2.9M 0.44% 37
2023
Q3
$868K Buy
6,704
+2,453
+58% +$327K 0.12% 158
2023
Q2
$527K Buy
+4,251
New +$572K 0.07% 283
2015
Q3
– Sell
-1,556
Closed -$274K – 232
2015
Q2
$274K Buy
+1,556
New +$279K 0.19% 141
2015
Q1
– Sell
-1,314
Closed -$215K – 203
2014
Q4
$215K Buy
+1,314
New +$218K 0.22% 122

Other funds holding JAZZ

Kovack Advisors's JAZZ Position: Q3 2026 in Review

Kovack Advisors held its Jazz Pharmaceuticals (JAZZ) position steady in Q3 2026 at 921 shares worth $214K. The position accounts for 0.01% of the portfolio, ranked #950.

Kovack Advisors first reported a position in JAZZ in Q4 2014 and has held it in 16 quarters since. The position peaked at $9.09M in Q4 2025. 668 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Kovack Advisors held 921 shares of Jazz Pharmaceuticals worth $214K as of Q3 2026.
  • Kovack Advisors left its Jazz Pharmaceuticals share count unchanged in Q3 2026.
  • Jazz Pharmaceuticals made up 0.01% of Kovack Advisors's portfolio in Q3 2026, its #950 holding.
  • Kovack Advisors first reported a position in Jazz Pharmaceuticals in Q4 2014 and has held it in 16 quarters since.
  • Kovack Advisors's Jazz Pharmaceuticals position peaked at $9.09M in Q4 2025.
  • 668 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Kovack Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.